In this study, we demonstrated that: (1) QLQX reduces platelet aggregation, spreading, clot retraction, and ex vivo thrombus formation in patients with CHF; (2) QLQX inhibits platelet activation in wild-type mice; (3) QLQX attenuates FeCl3-induced mesenteric arteriole thrombosis and collagen/epinephrine-induced pulmonary embolism, and reduces microvascular thrombosis and infarct size after myocardial I/R, without increasing bleeding in mice; (4) mechanistically, QLQX inhibit platelet Ca2+ influx and PKC signaling pathway. This evidence concerns the gene PRRT2 and congestive heart failure.